# US 2025/0042587 A1 · Topical formulations and methods for bioactive & bioavailable naringenin for treating skin conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0042587 A1
- Document ID: US20250042587A1
- Status: Published application
- Kind: A1
- Application number: 18/922,183
- Filed: 2024-10-21
- Published: 2025-02-06
- Earliest claimed: 2020-05-22
- Assignees: Protocol Lab, LLC
- Applicants: Protocol Lab, LLC
- Inventors: Tyler Thomas Gaul
- Web page: https://patentgrep.com/patent/US20250042587A1

## CPC

- B65B 31/025: {specially adapted for rigid or semi-rigid containers (B65B31/021, B65B31/022 take precedence)}
- B65B 1/04: Methods of, or means for, filling the material into the containers or receptacles
- B65B 57/00: Automatic control, checking, warning, or safety devices (registering wrapping or container-forming material fed from rolls B65B41/18)
- B65B 55/027: {Packaging in aseptic chambers}
- B65B: MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING (bundling and pressing devices for cigars A24C1/44; devices for tensioning and securing binders adapted to be supported by the article or articles to be bound B25B25/00; applying closure members to bottles, jars or similar containers B67B1/00-B67B6/00; concurrent cleaning, filling and closing of bottles B67C7/00; emptying bottles, jars, cans, casks, barrels or similar containers B67C9/00)

## Abstract

A method for treating a skin condition in a human patient. The method includes applying, to one or more affected areas of the human patient's skin, a naringenin formulation having an amount of naringenin effective to reduce or inhibit inflammatory processes.

## Claims

### Claim 1

A method for treating a skin condition in a human patient, the method comprising:
applying, to one or more affected areas of the human patient's skin, a naringenin formulation having an amount of naringenin effective to reduce or inhibit inflammatory processes.

### Claim 2 (depends on 1)

The method of claim 1, wherein the naringenin formulation is applied as an adjunct therapy to a topical or an oral corticosteroid.

### Claim 3 (depends on 1)

The method of claim 1, wherein the naringenin formulation is further applied as an adjunct therapy to a topical or an oral antibiotic.

### Claim 4 (depends on 1)

The method of claim 1, wherein the naringenin formulation is applied to the one or more affected areas from 1 to about 10 times daily.

### Claim 5 (depends on 4)

The method of claim 4, wherein the naringenin formulation is applied to affected areas from 1 to about 5 times daily.

### Claim 6 (depends on 1)

The method of claim 1, wherein the naringenin formulation further comprises naringin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the naringenin formulation does not include naringin.

### Claim 8 (depends on 1)

The method of claim 1, wherein the naringenin formulation is a water-based naringenin solution.

### Claim 9 (depends on 1)

The method of claim 1, wherein the skin condition is one or more of Rosacea, Ichthyosis, Actinic Keratosis, dermatitis, pruritus, psoriasis, or dermatitis herpetiformis.

### Claim 10

A method of packaging a skin treatment product for widespread consumer treatment, the method comprising:
providing an oxygen-free packaging environment;
providing one or more product packages within the oxygen-free packing environment, the one or more product packages being substantially non-gas permeable;
within the oxygen-free packing environment, substantially filling the one or more product packages with a naringenin formulation; and
sealing the one or more product packages so as to be substantially non-gas permeable.

### Claim 11 (depends on 10)

The method of claim 10, wherein the one or more product package are consumer-sized packages.

### Claim 12 (depends on 10)

The method of claim 10 further comprising providing a bulk product dispenser within the oxygen free packaging environment, the bulk product dispenser including a bulk portion of the naringenin formula for dispensing into the one or more product packages.

### Claim 13 (depends on 10)

The method of claim 10, wherein the naringenin formulation further comprises naringin.

### Claim 14 (depends on 10)

The method of claim 10, wherein the naringenin formulation does not include naringin.

### Claim 15 (depends on 10)

The method of claim 10, wherein the naringenin formulation is a water-based naringenin solution.

### Claim 16

A packaged treatment for treating a skin condition in a human patient, the packaged treatment comprising:
a product package that is substantially non-gas permeable; and
a naringenin formulation disposed within the product package,
wherein the naringenin formula was disposed within the product package within an oxygen-free environment.

### Claim 17 (depends on 16)

The packaged treatment of claim 16, wherein the naringenin formulation further comprises naringin.

### Claim 18 (depends on 16)

The method of claim 16, wherein the naringenin formulation does not include naringin.

### Claim 19 (depends on 16)

The method of claim 16, wherein the naringenin formulation is a water-based naringenin solution.

### Claim 20 (depends on 16)

The method of claim 16, wherein the skin condition is one or more of Rosacea, Ichthyosis, Actinic Keratosis, dermatitis, pruritus, psoriasis, or dermatitis herpetiformis.
